ADMA offers premium ASCENIV economics and major upside, but accounting litigation and leverage make the stock a highly speculative binary investment.
Overview
ADMA Biologics operates an integrated specialty plasma-biologics platform with three FDA-approved products: ASCENIV, BIVIGAM, and Nabi-HB. The investment case depends on ASCENIV’s premium, clinically differentiated position in refractory and medically complex patients, supported by proprietary donor screening, patents, and physician switching costs. **ASCENIV represented 83% of Q2 2026 revenue and grew 23.5% year over year to USD 102.9 million**, while BIVIGAM declined 48.5% to USD 19.4 million because of standard-IVIG pricing pressure. Q2 revenue rose 2.0% to USD 124.4 million, but missed the USD 126.0 million consensus estimate. Gross margin expanded to 69.0% from 55.0%, GAAP net income increased 11% to USD 37.8 million, and adjusted EBITDA rose 22% to USD 61.8 million. Management reiterated FY2026 revenue guidance of USD 530 million–560 million and adjusted EBITDA guidance of USD 265 million–300 million, below earlier projections. At the USD 8.91 share price, the stock offers substantial upside if demand is genuine, but the pending class-action litigation, related-party allegations, auditor resignation, CFO departure, and debt-funded buybacks make the risk/reward highly binary. Near-term catalysts include litigation developments, SG-001’s pre-IND package by year-end 2026, and BIVIGAM stabilization.